Request a Quotation

Your Contact Information
Peptides Logo
Support and counselling under:
+49(0)3302 - 2022000 info@peptides.de
€0.00*
Pool peptide logo
Logo for Cancer
Cancer

MAGEA4 Peptide Pool, human

Product number: LB01692

€277.50*

Prices excl. VAT plus shipping costs
Available, delivery time: 1-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Caution: For research use only. Not for use in humans.
1
Add to Cart

Description

Pool of 77 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma-associated antigen 4 (MAGEA4) (UniProt ID: P43358) of Homo sapiens (Human) for T cell assays.

One unit allows the stimulation of 2,5 x 108 cells.

TechData

Gene: MAGEA4
Delivery: 1-3 days
Counterion: TFA
Length: 317 amino acids
No. Peptides: 77 peptides
Amount/Aliquote: 15 nmol (approx. 25µg)/peptide for stimulation of 2,5 x 108 cells
Solubility: Dissolve in a minimum amount of pure DMSO (40µl) and dilute with water to the desired concentration. Please pay attention that the final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological system.
Protein: Melanoma-associated antigen 4
UniProt Id: P43358
Species: Human
Application: T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication: Cancer

Documents

Material data sheet Safety data sheet Storage and handling of peptides Probing of membranes with HRP
Skip product gallery

More MAGE peptides

MAGE - A2 mutant (157-166) 161I
MAGE - A2 mutant (157-166) 161I
The peptide MAGE - A2 mutant (157-166) 161I with the amino acid sequence YLQLIFGIEV is a linear peptidic epitope (epitope ID 74879).MAGE - A2 mutant (157-166) 161I has been studied for immune reactivity in publication and has been tested in T cell assay and MHC ligand assay.

From €105.00*
Details
MAGE 212-220 (HLA-C*07:01)
MAGE 212-220 (HLA-C*07:01)
This Peptide MAGE HLA-C*07:01 (EGDCAPEEK) is for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
MAGE-A1 161-169 (HLA-A*01:01)
MAGE-A1 161-169 (HLA-A*01:01)
EADPTGHSY is a linear peptidic epitope (epitope ID11010) studied as part of Melanoma-associated antigen 1 from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
MAGE-A1 278-286 (HLA-A*02:01)
MAGE-A1 278-286 (HLA-A*02:01)
KVLEYVIKV is a linear peptidic epitope (epitope ID34095) studied as part of Melanoma-associated antigen 1 from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in MHC ligand assays

From €105.00*
Details
MAGE-A1 289-298 (HLA-B*07:02)
MAGE-A1 289-298 (HLA-B*07:02)
RVRFFFPSL is a linear peptidic epitope (epitope ID179897) studied as part of Melanoma-associated antigen 1 from Homo sapiens (human), tested in MHC ligand assays

From €105.00*
Details
MAGE-A1-3/A5 Mouse Kb/Db
MAGE-A1-3/A5 Mouse Kb/Db
LGITYDGM is a linear peptidic epitope studied as part of MageA2 protein from Mus musculus (mouse), tested in T cell assays and MHC ligand assay.

From €105.00*
Details
MAGE-A2 156-164 (HLA-A*24:02)
MAGE-A2 156-164 (HLA-A*24:02)
EYLQLVFGI is a linear peptidic epitope (epitope ID15058) studied as part of Melanoma-associated antigen 2 from Homo sapiens (human), tested in MHC ligand assays

From €105.00*
Details
MAGE-A2 157-166 (HLA-A*02:01)
MAGE-A2 157-166 (HLA-A*02:01)
YLQLVFGIEV is a linear peptidic epitope (epitope ID74881) studied as part of Melanoma-associated antigen 12 from Homo sapiens (human) and Melanoma-associated antigen 2 from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
MAGE-A3 112-120 (HLA-A*02:01)
MAGE-A3 112-120 (HLA-A*02:01)
KVAELVHFL is a linear peptidic epitope (epitope ID33943) studied as part of Melanoma-associated antigen 9 from Homo sapiens (human) and Melanoma-associated antigen 3 from Homo sapiens (human). This epitope has been studied for immune reactivity in, tested in T cell assays and MHC ligand assays Antigen Peptide MAGE-A3 112-120 (HLA-A*02:01) KVAELVHFL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.KVAELVHFL is a linear peptidic epitope (epitope ID33943) studied as part of Melanoma-associated antigen 9 from Homo sapiens (human) and Melanoma-associated antigen 3 from Homo sapiens (human). This epitope has been studied for immune reactivity in, tested in T cell assays and MHC ligand assays Antigen Peptide MAGE-A3 112-120 (HLA-A*02:01) KVAELVHFL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
MAGE-A3 112-120 mutant (HLA-A*02:01)
MAGE-A3 112-120 mutant (HLA-A*02:01)
This peptide has a high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This product is a MHC pentamer of peptide composed MAGE-A3 derived peptide of KVAEELVHFL sequence covering 112-120 and A*02:01 molecule.

From €105.00*
Details
MAGE-A3 168-176 (HLA-A*01:01)
MAGE-A3 168-176 (HLA-A*01:01)
EVDPIGHLY is a linear peptidic epitope (epitope ID14672) studied as part of Melanoma-associated antigen 3 from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
MAGE-A3 271-279 (HLA-A*02:01)
MAGE-A3 271-279 (HLA-A*02:01)
FLWGPRALV is a linear peptidic epitope (epitope ID16970) studied as part of Melanoma-associated antigen 3 from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
MAGE-A3 97-105 (HLA-A*24:02)
MAGE-A3 97-105 (HLA-A*24:02)
The peptide MAGE-A3 97-105 (HLA-A*24:02) with the amino acid sequence TFPDLESEF is a linear peptidic epitope (epitope ID 727908) studied as part of Melanoma-associated antigen 3 (UniProt:P43357) from Homo sapiens (human) and Melanoma-associated antigen 6 (UniProt:P43360) from Homo sapiens (human).MAGE-A3 97-105 (HLA-A*24:02) has been studied for immune reactivity in publications and has been tested in T cell assays and MHC ligand assays.

From €105.00*
Details
MAGE-A4 230–239 (HLA-A*02:01)
MAGE-A4 230–239 (HLA-A*02:01)
Amount in mg: 1 mg
GVYDGREHTV is a linear peptidic epitope (epitope ID95091) studied as part of Melanoma-associated antigen 4 from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in MHC ligand assays

€105.00*
MAGE-C1 1087-1095 (HLA-A*02:01)
MAGE-C1 1087-1095 (HLA-A*02:01)
The peptide MAGE-C1 1087-1095 (HLA-A*02:01) with the amino acid sequence FLAMLKNTV is a linear peptidic epitope (epitope ID 2188154) studied as part of Melanoma-associated antigen C1 (UniProt:O60732) from Homo sapiens (human).MAGE-C1 1087-1095 (HLA-A*02:01) has been studied for immune reactivity in publication and has been tested in T cell assays.

From €105.00*
Details
MAGE-C2 191-200 (HLA-A*2)
MAGE-C2 191-200 (HLA-A*2)
This peptide has a high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This product is a MHC pentamer of peptide composed MAGEC2-derived peptide of LLFGLALIEV sequence covering 191-200 and A*02:01 molecule.

From €105.00*
Details
MAGEA-10 254-262 (HLA-A*02:01)
MAGEA-10 254-262 (HLA-A*02:01)
GLYDGMEHL is a linear peptidic epitope (epitope ID189401) studied as part of Melanoma-associated antigen 10 from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in MHC ligand assays

From €105.00*
Details
MAGEA1 Peptide Pool, human
MAGEA1 Peptide Pool, human
Pool of 75 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma-associated antigen 1 (MAGEA1) (UniProt ID: P43355) of Homo sapiens (Human) for T cell assays One unit allows the stimulation of 2,5 x 108 cells.

€277.50*
MAGEA10 Peptide Pool, human
MAGEA10 Peptide Pool, human
Pool of 90 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma-associated antigen 10 (MAGEA10) (UniProt ID: P43363) of Homo sapiens (Human) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€361.60*
MAGEA11 Peptide Pool, human
MAGEA11 Peptide Pool, human
Pool of 105 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma-associated antigen 11 (MAGEA11) (UniProt ID: P43364) of Homo sapiens (Human) for T cell assays One unit allows the stimulation of 2,5 x 108 cells.

€361.60*
MAGEA3 Peptide Pool, human
MAGEA3 Peptide Pool, human
Pool of 76 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma-associated antigen 3 (MAGEA3) (UniProt ID: P43357) of Homo sapiens (Human) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.You can find applications and references in our blog post: Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I Expression

€277.50*
MAGEA6 Peptide Pool, human
MAGEA6 Peptide Pool, human
Pool of 76 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma-associated antigen 6 (UniProtKB - P43360) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells. You can find applications and references in our blog post: Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I Expression

€316.90*
MAGEC1 Peptide Pool, human
MAGEC1 Peptide Pool, human
Pool of 283 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma-associated antigen C1 (MAGEC1, UniProt ID: O60732) of Homo sapiens for T cell assays (e.g. ELISPOT). One unit allows the stimulation of 2,5 x 108 cells.

€316.90*
MAGED1 Peptide Pool, human
MAGED1 Peptide Pool, human
Pool of 192 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma-associated antigen D1 (MAGED1, UniProt: Q9Y5V3) of Homo sapiens for T cell assays (e.g. ELISPOT). One unit allows the stimulation of 2,5 x 108 cells.

€316.90*
This website uses cookies to ensure the best experience possible. More information...